Literature DB >> 28006863

Concordant and discordant familial cancer: Familial risks, proportions and population impact.

Christoph Frank1, Jan Sundquist2,3, Hongyao Yu1, Akseli Hemminki4,5, Kari Hemminki1,2.   

Abstract

Relatives of cancer patients are at an increased risk of the same (concordant) cancer but whether they are at a risk for different (discordant) cancers is largely unknown - beyond well characterized hereditary cancer syndromes - but would be of major scientific and clinical interest. We therefore decided to resolve the issue by analyzing familial risks when family members were diagnosed with any discordant cancers. We compared the population impact of concordant to discordant familial cancer. The Swedish Family-Cancer Database (FCD) was used to calculate familial relative risks (RRs) for family members of cancer patients, for the 27 most common cancers. Population attributable fractions (PAFs) were estimated for concordant and discordant family histories. Discordant cancers in the family were detected as significant risk factors for the majority of cancers, although the corresponding RRs were modest compared to RRs for concordant cancers. Risks increased with the number of affected family members with the highest RRs for pancreatic (2.31), lung (1.69), kidney (1.98), nervous system (1.79) and thyroid cancers (3.28), when 5 or more family members were diagnosed with discordant cancers. For most cancers, the PAF for discordant family history exceeded that for concordant family history. Our findings suggest that there is an unspecific genetic predisposition to cancer with clinical consequences. We consider it unlikely that shared environmental risk factors could essentially contribute to the risks for diverse discordant cancers, which are likely driven by genetic predisposition. The identification of genes that moderately increase the risk for many cancers will be a challenge.
© 2016 UICC.

Entities:  

Keywords:  discordant cancer; familial cancer; familial risk; population impact

Mesh:

Year:  2017        PMID: 28006863     DOI: 10.1002/ijc.30583

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma.

Authors:  Craig C Teerlink; Chad Huff; Jeff Stevens; Yao Yu; Sheri L Holmen; Mark R Silvis; Kirby Trombetti; Hua Zhao; Douglas Grossman; James M Farnham; Jingran Wen; Julio C Facelli; Alun Thomas; Markus Babst; Scott R Florell; Laurence Meyer; John J Zone; Sancy Leachman; Lisa A Cannon-Albright
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

2.  Metagenomic Analyses of Multiple Gut Datasets Revealed the Association of Phage Signatures in Colorectal Cancer.

Authors:  Wenxuan Zuo; Sonia Michail; Fengzhu Sun
Journal:  Front Cell Infect Microbiol       Date:  2022-06-15       Impact factor: 6.073

3.  Family history of any cancer for childhood leukemia patients in Sweden.

Authors:  Xinjun Li; Kristina Sundquist; Jan Sundquist; Asta Försti; Kari Hemminki
Journal:  EJHaem       Date:  2021-05-03

4.  Family Study Designs Informed by Tumor Heterogeneity and Multi-Cancer Pleiotropies: The Power of the Utah Population Database.

Authors:  Heidi A Hanson; Claire L Leiser; Michael J Madsen; John Gardner; Stacey Knight; Melissa Cessna; Carol Sweeney; Jennifer A Doherty; Ken R Smith; Philip S Bernard; Nicola J Camp
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-25       Impact factor: 4.254

5.  Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models.

Authors:  Puzi Jiang; Sicheng Wu; Qibin Luo; Xing-Ming Zhao; Wei-Hua Chen
Journal:  mSystems       Date:  2021-05-04       Impact factor: 6.496

6.  Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation.

Authors:  Andrew Maltez Thomas; Paolo Manghi; Francesco Asnicar; Edoardo Pasolli; Federica Armanini; Moreno Zolfo; Francesco Beghini; Serena Manara; Nicolai Karcher; Chiara Pozzi; Sara Gandini; Davide Serrano; Sonia Tarallo; Antonio Francavilla; Gaetano Gallo; Mario Trompetto; Giulio Ferrero; Sayaka Mizutani; Hirotsugu Shiroma; Satoshi Shiba; Tatsuhiro Shibata; Shinichi Yachida; Takuji Yamada; Jakob Wirbel; Petra Schrotz-King; Cornelia M Ulrich; Hermann Brenner; Manimozhiyan Arumugam; Peer Bork; Georg Zeller; Francesca Cordero; Emmanuel Dias-Neto; João Carlos Setubal; Adrian Tett; Barbara Pardini; Maria Rescigno; Levi Waldron; Alessio Naccarati; Nicola Segata
Journal:  Nat Med       Date:  2019-04-01       Impact factor: 87.241

7.  Two novel colorectal cancer risk loci in the region on chromosome 9q22.32.

Authors:  Jessada Thutkawkorapin; Hovsep Mahdessian; Tom Barber; Simone Picelli; Susanna von Holst; Johanna Lundin; Laura Valle; Vinaykumar Kontham; Tao Liu; Daniel Nilsson; Xiang Jiao; Annika Lindblom
Journal:  Oncotarget       Date:  2018-01-29

8.  Host DNA contents in fecal metagenomics as a biomarker for intestinal diseases and effective treatment.

Authors:  Puzi Jiang; Senying Lai; Sicheng Wu; Xing-Ming Zhao; Wei-Hua Chen
Journal:  BMC Genomics       Date:  2020-05-11       Impact factor: 3.969

9.  Familial risks of second primary cancers and mortality in ovarian cancer patients.

Authors:  Guoqiao Zheng; Subhayan Chattopadhyay; Asta Försti; Kristina Sundquist; Kari Hemminki
Journal:  Clin Epidemiol       Date:  2018-10-11       Impact factor: 4.790

10.  Familial risks of ovarian cancer by age at diagnosis, proband type and histology.

Authors:  Guoqiao Zheng; Hongyao Yu; Anna Kanerva; Asta Försti; Kristina Sundquist; Kari Hemminki
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.